Table 2

Characteristics of the subjects with AATD and COPD

CharacteristicAATD (n=471)AATD with COPD (n=364)AATD without COPD (n=107)AATD subset (n=60)COPD (n=140)
Age50.33 (10.35)51.75 (9.33)43.46 (36.37–56.36)49.71 (9.88)68.82 (0.93)
Male gender281 (59.70)233 (64.00)57 (53.27)37 (61.67)79 (56.61)
Pack-years smoked15.00 (2.25–25.0)18.00 (9.00–26.81)0 (0–10.38)21.00 (13.65–27.25)43.50 (31.72–58.00)
FEV1 % predicted45.30 (28.45–72.33)36.70 (25.86–52.74)104.91 (18.63)35.66 (22.38–56.41)43.43 (15.84)
FEV1/FVC39.00 (29.00–56.00)34.00 (27.00–44.75)80.00 (71.00–85.50)34.00 (26.75–48.25)36.00 (28.72–51.00)
COPD364 (78.62)364 (100)049 (81.67)140 (100)
Bronchiectasis*111 (25.20)88 (24.20)22 (25.00)20 (33.33)8 (18.6)
Airway bacterial colonisation*52 (69.31)45 (67.16)6 (85.71)26 (68.41)
Exacerbations per year1.00 (0–2)1.00 (0–2)1.00 (0–2)1.00 (1–2)2.00 (1–4)
  • The table shows the mean (SD) or median (IQR) for all quantitative outcomes, and number (%) for the qualitative outcomes, these being gender, COPD, emphysema, bronchiectasis and airway bacterial colonisation. Mean (SD) is shown where data are normally distributed, and median (IQR) where they are non-normal.

  • * Percentages shown as a proportion of scans and sputum obtained, respectively.

  • AATD, α1-antitrypsin deficiency; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.